InpharmD™

Evidence Based Medicine presented by InpharmD™

Health EN ↓ 78 Folgen

We take the most popularly asked clinical questions monthly and create a class around the corresponding evidence. Our EBM podcast will offer a glimpse into the evidence covered, and listeners can follow up with our CE if interested in more information.

Besuch unbedingt die Website des Podcasts und unterstütze die Macher: inpharmd.libsyn.com

Autor

InpharmD™

Kategorie

Health

Podcast-Website

inpharmd.libsyn.com

Neueste Folge

28. Aug 2024

Wo hören?

Podcasts in der App Replaio Radio Bald verfügbar

Podcasts kommen bald in die App. Installiere sie jetzt und erlebe als Erster einen ganz neuen Blick auf Podcasts

Bei Google Play herunterladen Kostenlos installieren Android fast 10 Mio. Downloads · Bewertung 4,8 iOS bald

Folgen

Ketamine for Sickle Cell Disease 28.08.2024

InpharmD's EBM podcast focuses on commonly asked drug information questions and the associated literature. This episode focuses on the use of ketamine for Sickle Cell Disease. 

Tirzepatide for Sleep Apnea 26.07.2024

InpharmD's EBM podcast focuses on commonly asked drug information (DI) questions and the associated literature. Everyday, our queue gets tons of questions asked by health care providers all around the country. For this episode, we assess tirzepatide for obstructive sleep apnea and analyze the SURMOUNT-OSA clinical trials. 

Excoriation Disorder 28.05.2024

InpharmD's EBM podcast focuses on commonly asked drug information (DI) questions and the associated literature. Everyday, our queue gets tons of questions asked by health care providers all around the country. For this episode, we assess treatment options for excoriation disorder.

Phenytoin for Tacrolimus Toxicity 25.04.2024

InpharmD's EBM podcast focuses on commonly asked DI questions. Every day, our queue gets tons of new questions asked from providers all around the country. Today's podcast focuses on the use of phenytoin to treat tacrolimus toxicity. 

Atypical Antipsychotics and QT–prolongation 27.02.2024

InpharmD's EBM podcast focuses on commonly asked drug information questions. Every day, our queue gets tons of new questions asked from providers all around the country. One question that's been garnering a lot of views from our users right now is which atypical antipsychotics are associated with the lowest and highest risk of QT prolongation.

Apixaban in Peripheral Artery Disease 30.11.2023

Join InpharmD as we discuss the role of apixaban in peripheral artery disease.

Safety and Efficacy of RSV Vaccines 27.09.2023

Join InpharmD as we discuss the safety and efficacy of two FDA-approved RSV vaccines, Arexvy and Abrysvo.

Safety and Efficacy of Rezafungin 20.07.2023

Join us as we discuss the data surrounding newly approved antifungal agent, rezafungin. Interested in learning more? Join our CE on rezafungin on July 27th at 12:00 PM EST - open to all pharmacists! 

Perioperative Duloxetine During Orthopedic Surgery for Pain Reduction 13.06.2023

Join InpharmD as we discuss the data on perioperative duloxetine (Cymbalta) during orthopedic surgery for pain reduction.  Interested in the full data response? Read here ! 

Lecanemab in the treatment of Alzheimer's Dementia 17.04.2023

Every month, InpharmD creates a continuing-education (CE) class on the most commonly asked drug information question and the related evidence. Our podcast offers a sneak peak into our CE as we briefly discuss the topic.  Episode-2 looks at the safety and efficacy of lecanemab in the treatment of Alzheimer's dementia.

Tirzepatide for Weight Loss in Diabetic Patients 06.03.2023

Join us as we discuss the evidence surrounding tirzepatide for weight loss in diabetic patient populations. 

Yet Another Drug Shortage? Alternatives to Oxytocin 14.10.2022

Many hospitals have been dealing with the recent oxytocin shortage. With this episode, we discuss possible alternatives and adjuncts to oxytocin, based on the evidence available. 

Can Evusheld Increase Cardiovascular Events? 26.09.2022

Tune in as we discuss the PROVENT trial and the on-going TACKLE trial to determine whether or not Evusheld can increase cardiovascular events.

Could Intermittent Fasting be the Next Big Weight Loss Tool? 21.06.2022

A randomized clinical trial conducted to assess time-restricted eating with calorie restriction as compared with daily calorie restriction alone for the effects on weight loss and metabolic risk factors in obese patients.

A 4th Dose of the COVID-19 Vaccine 29.04.2022

A regression analysis conducted in Israel showed that a fourth dose appeared to increase the protection against severe illness relative to three doses that were administered more than 4 months earlier. Further studies are needed before applying this to a larger population. 

A Possible Alternative for Recurrent Urinary Tract Infections 21.04.2022

A multicenter, randomized, open label, non-inferiority trial conducted to test and compare the efficacy of methenamine hippurate for prevention of recurrent urinary tract infections (UTI) with the current standard prophylaxis of daily low dose antibiotics.

Estimation of Breast Cancer Overdiagnosis 25.03.2022

A cohort study conducted to estimate the rate of breast cancer overdiagnosis in contemporary mammography practice accounting for the detection of nonprogressive cancer.

Can Ketamine Treat Acute, Severe Suicidal Ideation? 14.03.2022

A prospective, double blind, superiority, randomized placebo-controlled trial conducted to confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks.

Could SER-109 be an Answer for Recurrent C.Difficile Infection? 22.02.2022

A phase 3, double-blind, randomized, placebo-controlled trial conducted to show superiority of SER-109 in reducing the risk of C. difficile infection recurrence up to 8 weeks after treatment. 

To Boost or not to Boost - That is the Question 11.02.2022

A retrospective study conducted to assess for any decrease in mortality associated with the use of the BNT162b2 (BioNTech, Pfizer  vaccine) booster.

Old Dogs Can Learn New Tricks: Is Outpatient Remdesivir a Game Changer against Omicron? 20.01.2022

A double-blind, randomized, placebo-controlled trial conducted to evaluate the efficacy and safety of a 3-day course of remdesivir in high-risk, non-hospitalized patients with COVID-19.

Can Financial Incentives Help Pregnant Patients Quit Smoking? 06.01.2022

A single-blind, multicenter, randomized, controlled trial conducted to evaluate the efficacy of financial incentives dependent on continuous smoking abstinence on smoking cessation and birth outcomes among pregnant smokers.   

Milvexian for the Prevention of Venous Thromboembolism 22.12.2021

An open-label, randomized, parallel-group, adaptive design with blinded outcome adjudication trial conducted to compare the efficacy and safety of milvexian and enoxaparin in patients undergoing elective knee arthroplasty. 

Merck's New COVID-19 Pill - Molnupiravir 01.12.2021

The first in-human, phase 1, randomized, double-blind, placebo-controlled study conducted to determine the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of molnupiravir in healthy subjects.

Can chlorthalidone therapy improve blood-pressure control in patients with advanced CKD? 25.11.2021

A double-blind, randomized, placebo-controlled trial conducted to assess the role of chlorthalidone for hypertension in advanced chronic kidney disease. 

Höre den Podcast Evidence Based Medicine presented by InpharmD™ in Replaio

Radio und Podcasts in einer App - kostenlos und ohne Anmeldung. Installiere sie noch heute und verpasse den Start nicht

Bei Google Play herunterladen

Replaio ist kein Herausgeber von Podcasts; die Namen der Sendungen, Cover und Audioinhalte gehören ihren Autoren und werden über öffentliche RSS-Feeds verbreitet